XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.2

Industry Segment Information (Tables)

6 Months Ended

Jun. 29, 2025

Segment Reporting [Abstract]

Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations

Revenue and operating income, including significant segment expenses, by reportable segment are shown in the table below:  

			Three Months Ended
			June 29, 2025																		June 30, 2024
			Life Sciences						Diagnostics						Total						Life Sciences						Diagnostics						Total
			(In thousands)
Segment revenue			$	365,898					$	354,386					$	720,284					$	348,525					$	343,160					$	691,685
Segment cost of revenue			135,028						156,039												120,427						146,294
Segment selling, general and administrative expenses			86,986						84,127												84,167						83,071
Segment research and development expenses			28,415						24,798												26,364						21,046
Segment operating income			$	115,469					$	89,422					204,891						$	117,567					$	92,749					210,316
Corporate expenses															(13,089)																		(11,449)
Amortization of intangible assets															(85,289)																		(90,620)
Purchase accounting adjustments															(2,178)																		(623)
Acquisition and divestiture-related costs															(1,248)																		(5,779)
Significant litigation matters and settlements															(1,124)																		(6,276)
Restructuring and other, net															(11,203)																		(9,845)
Interest and other (expense) income, net															(22,110)																		938
Income from continuing operations before income taxes															$	68,650																	$	86,662

			Six Months Ended
			June 29, 2025																		June 30, 2024
			Life Sciences						Diagnostics						Total						Life Sciences						Diagnostics						Total
			(In thousands)
Segment revenue			$	706,293					$	678,753					$	1,385,046					$	685,039					$	656,566					$	1,341,605
Segment cost of revenue			254,349						291,230												243,988						277,183
Segment selling, general and administrative expenses			174,081						174,017												170,104						165,880
Segment research and development expenses			56,683						50,069												52,429						44,550
Segment operating income			$	221,180					$	163,437					384,617						$	218,518					$	168,953					387,471
Corporate expenses															(22,904)																		(22,810)
Amortization of intangible assets															(167,989)																		(181,858)
Purchase accounting adjustments															(2,001)																		(7,245)
Acquisition and divestiture-related costs															(3,789)																		(17,241)
Significant litigation matters and settlements															(11,710)																		(6,276)
Significant environmental matters															1,208																		—
Restructuring and other, net															(14,442)																		(22,201)
Interest and other expense, net															(41,958)																		(8,629)
Income from continuing operations before income taxes															$	121,032																	$	121,211

Schedule of Depreciation [Table Text Block]

Depreciation expense included in the Company’s reportable segment operating income and corporate expenses is as follows:

			Three Months Ended												Six Months Ended
			June 29, 2025						June 30, 2024						June 29, 2025						June 30, 2024
			(In thousands)
Life Sciences			$	8,547					$	8,124					$	15,732					$	16,394
Diagnostics			8,279						7,999						15,125						15,701
Corporate			665						601						1,356						1,192
Total depreciation expense			$	17,491					$	16,724					$	32,213					$	33,287

X

- Definition

Schedule of Depreciation

+ References

No definition available.

+ Details

Name:	revv_ScheduleOfDepreciationTableTextBlock
Namespace Prefix:	revv_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration